Skip to main content
. Author manuscript; available in PMC: 2024 Feb 17.
Published in final edited form as: Vaccine. 2023 Jan 31;41(8):1513–1523. doi: 10.1016/j.vaccine.2023.01.059

Figure 1:

Figure 1:

Antibody responses to ZEBOV-GP by ELISA

A: Comparison of ZEBOV-GP IgG ODs between ZEBOV vaccine naïve and ZEBOV vaccine experienced participants. B: Fold changes in ZEBOV-GP IgG ODs post-vaccination compared to baseline according to ZEBOV vaccination status at enrollment. C: Comparison of ZEBOV-GP IgM ODs between ZEBOV vaccine naïve and ZEBOV vaccine experienced participants. D: Fold changes in ZEBOV-GP IgM ODs post-vaccination compared to baseline according to ZEBOV vaccination status at enrollment. All ODs reflect a 1:100 serum dilution. Dotted line indicates the OD criterion used to define a positive antibody response to vaccination (at least three standard deviations above the mean OD at baseline value of ZEBOV vaccine naïve participants)